University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

Other drugs, such as BMS and Innate's lirilumab/Opdivo combination, aim to stimulate the body's natural killer cells to fight cancer - but the future of this therapy is uncertain after ...

The Fast Track designation is supported by data from the open-label phase 1 SNK01-MX04 trial, as well as preliminary data from the phase 1 cohort from the phase 1/2a SNK01-AD01 trial.

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as monotherapy and in combination with rituximab among patients with B-cell ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without customization. However, some NK companies, such as Fate Therapeutics and Cytovia ...

The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s ...

The therapy is a bispecific antibody that targets both CD30 on lymphoma cells and CD16 on NK cells, which in this trial is given alongside cord blood-derived NK cells to stimulate an attack on the ...

“So natural killer cells from one donor could be potentially used to treat multiple patients,” Rezvani explains. “That could really reduce the cost of therapy and provide a readily available ...

Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory ...

For the new therapy, these cells are derived from stem cells that originated from healthy adult donor tissue - called induced pluripotent stem cells (iPSCs) - to make therapeutic CAR-NK cells.